Tags

Type your tag names separated by a space and hit enter

Aliskiren for renin inhibition: a new class of antihypertensives.
Ann Pharmacother. 2007 Mar; 41(3):456-64.AP

Abstract

OBJECTIVE

To review the safety, efficacy, pharmacology, pharmacokinetics, and drug interactions of aliskiren for the treatment of mild-to-moderate hypertension.

DATA SOURCES

A literature search was conducted using MEDLINE (1966-January 2007), International Pharmaceutical Abstracts (1970-January 2007), and Cochrane database (2006) for the key words aliskiren or SPP100. References of selected articles were also reviewed. Abstract data were included only in the absence of significant published data.

STUDY SELECTION AND DATA EXTRACTION

Available English-language data from reviews, abstracts, and clinical trials were selected. For review of efficacy, randomized controlled trials were preferred.

DATA SYNTHESIS

Aliskiren is a renin inhibitor, the first in a new class of antihypertensives. As renin catalyzes the rate-limiting step of the renin-angiotensin system (RAS), renin inhibition may offer a theoretical advantage over other RAS inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). In short-term clinical trials (< or =8 wk) of subjects with mild-to-moderate hypertension, single daily doses of aliskiren 150-300 mg produced significant systolic and diastolic blood pressure reduction similar to that achieved with ACE inhibitors and ARBs, with placebo-like tolerability, without an elevation in heart rate or evidence of tolerance.

CONCLUSIONS

Aliskiren appears to be a safe and effective treatment option in mild-to-moderate hypertension. Although long-term outcome data have not been published, aliskiren is a promising option for RAS inhibition.

Authors+Show Affiliations

Experimental Cardiovascular Pharmacotherapy, Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA. vantassell@pharm.utah.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17341529

Citation

Van Tassell, Benjamin W., and Mark A. Munger. "Aliskiren for Renin Inhibition: a New Class of Antihypertensives." The Annals of Pharmacotherapy, vol. 41, no. 3, 2007, pp. 456-64.
Van Tassell BW, Munger MA. Aliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother. 2007;41(3):456-64.
Van Tassell, B. W., & Munger, M. A. (2007). Aliskiren for renin inhibition: a new class of antihypertensives. The Annals of Pharmacotherapy, 41(3), 456-64.
Van Tassell BW, Munger MA. Aliskiren for Renin Inhibition: a New Class of Antihypertensives. Ann Pharmacother. 2007;41(3):456-64. PubMed PMID: 17341529.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aliskiren for renin inhibition: a new class of antihypertensives. AU - Van Tassell,Benjamin W, AU - Munger,Mark A, Y1 - 2007/03/06/ PY - 2007/3/8/pubmed PY - 2007/5/3/medline PY - 2007/3/8/entrez SP - 456 EP - 64 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 41 IS - 3 N2 - OBJECTIVE: To review the safety, efficacy, pharmacology, pharmacokinetics, and drug interactions of aliskiren for the treatment of mild-to-moderate hypertension. DATA SOURCES: A literature search was conducted using MEDLINE (1966-January 2007), International Pharmaceutical Abstracts (1970-January 2007), and Cochrane database (2006) for the key words aliskiren or SPP100. References of selected articles were also reviewed. Abstract data were included only in the absence of significant published data. STUDY SELECTION AND DATA EXTRACTION: Available English-language data from reviews, abstracts, and clinical trials were selected. For review of efficacy, randomized controlled trials were preferred. DATA SYNTHESIS: Aliskiren is a renin inhibitor, the first in a new class of antihypertensives. As renin catalyzes the rate-limiting step of the renin-angiotensin system (RAS), renin inhibition may offer a theoretical advantage over other RAS inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). In short-term clinical trials (< or =8 wk) of subjects with mild-to-moderate hypertension, single daily doses of aliskiren 150-300 mg produced significant systolic and diastolic blood pressure reduction similar to that achieved with ACE inhibitors and ARBs, with placebo-like tolerability, without an elevation in heart rate or evidence of tolerance. CONCLUSIONS: Aliskiren appears to be a safe and effective treatment option in mild-to-moderate hypertension. Although long-term outcome data have not been published, aliskiren is a promising option for RAS inhibition. SN - 1542-6270 UR - https://www.unboundmedicine.com/medline/citation/17341529/Aliskiren_for_renin_inhibition:_a_new_class_of_antihypertensives_ L2 - https://journals.sagepub.com/doi/10.1345/aph.1H549?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -